title: Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.
abstract: OBJECTIVE
  To evaluate the efficacy of 1 intravitreal injection of ranibizumab monthly for 3 months in eyes with polypoidal choroidal vasculopathy (PCV), with attention to changes on indocyanine green angiography (ICGA) with confocal scanning laser ophthalmoscopy (cSLO).
  
  
  METHODS
  Prospective, consecutive case series.
  
  
  METHODS
  Fifty consecutive eyes of 50 patients with symptomatic PCV who had not been treated previously received 1 intravitreal injection of 0.5 mg ranibizumab monthly for 3 months. Changes in ICGA findings with cSLO 3 months after the primary injection were evaluated.
  
  
  RESULTS
  The mean visual acuity (VA) at baseline (0.25; range, 0.1-0.8) improved to 0.38 (P = .001) 3 months after the primary injection. Nineteen eyes (38%) had an improvement in VA of 0.3 or more logMAR unit, and 5 eyes (10%) had a decrease in VA of 0.3 or more logMAR unit. Polypoidal lesions disappeared on ICGA in 13 eyes (26%) and the number of lesions decreased but did not disappear in 26 eyes (52%), with absorption of the accompanying fluid on optical coherence tomography. The remaining 11 eyes (22%) had unchanged or worsened polypoidal lesions. A branching vascular network remained in all 48 eyes in which the network was detected at baseline. Although resolution of the branching vascular networks or decreased diameter of the branching vascular network occurred in 11 eyes (23%), the branching vascular network was unchanged or worse in 37 eyes (77%).
  
  
  CONCLUSIONS
  Although a limitation of this study is the short-term follow-up, polypoidal lesions tended to respond to ranibizumab therapy, but the branching vascular network responded poorly.
authors.affiliation: Ohtsuka Eye Hospital, Sapporo, Japan. taiichi-hikichi@hokkaido.med.or.jp
authors.forename: Taiichi
authors.initials: T
authors.lastname: Hikichi
authors.forename: Hideo
authors.initials: H
authors.lastname: Ohtsuka
authors.forename: Makoto
authors.initials: M
authors.lastname: Higuchi
authors.forename: Takuro
authors.initials: T
authors.lastname: Matsushita
authors.forename: Hiroko
authors.initials: H
authors.lastname: Ariga
authors.forename: Shoko
authors.initials: S
authors.lastname: Kosaka
authors.forename: Reiko
authors.initials: R
authors.lastname: Matsushita
authors.forename: Kimitaka
authors.initials: K
authors.lastname: Takami
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D002829:Choroid / Q000098:blood supply*; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy*; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D007267:Injections; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy; D016491:Peripheral Vascular Diseases / Q000175:diagnosis / Q000188:drug therapy*; D011127:Polyps / Q000175:diagnosis / Q000188:drug therapy; D011446:Prospective Studies; D000069579:Ranibizumab; D019233:Retreatment; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D007208:Indocyanine Green; D000069579:Ranibizumab